Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 610 participants.

Also called NCT05360446

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 610 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05360446
  • EudraCT 2021-004601-47
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Hungary, India, Ireland, Italy, Japan, South Korea, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05360446. Randomized; triple masking; primary purpose treatment. Start 2022-07-08 (actual); primary completion 2026-10-26 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Acronym
V-PLAQUE
Intervention (Drug)
Inclisiran sodium 300 mg
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05360446
Content hash
ad6e49679456d4f0548e868ab060202f568a93458d36eda94b5e0b1b4361e060